Literature DB >> 11545623

Immunohistochemical localization of the prostacyclin receptor (IP) human bone.

I Fortier1, C Patry, M Lora, R Samadfan, A J de Brum-Fernandes.   

Abstract

Prostacyclin (PGI(2)) is an important mediator implicated in bone metabolism. Among the natural prostaglandins it is the most potent inhibitor of bone resorption and mediates bone modelling and remodelling induced by strain changes. The effects of prostacyclin depend on its interaction with a specific receptor (IP). Despite its well documented effects on bone the localization and distribution of the IP receptor in human bone remain unknown. The present study used specific antipeptide antibodies to IP receptor for immunolocalization of the IP receptor in normal, osteoporotic and Pagetic human adult bone and in human fetal bone. The IP receptor was detected in fetal and adult osteoclasts and osteoblasts. Fetal osteocytes also expressed IP receptor but not adult osteocytes. Interestingly, the expression of IP receptor in adult osteoblasts was gradually lost as these cells were trapped in the matrix and became osteocytes. The IP receptor showed a perinuclear distribution within the cells, but in multinuclear osteoclasts not all nuclei were positive. Our results showed differences in IP receptor expression in fetal and adult human bone and, in adult bone, with the differentiation of osteoblasts into osteocytes. They also showed that there is no difference on the expression of prostacyclin receptors in Pagetic, osteoporotic and normal human bone, and they confirm the presence of the IP receptor in human osteoblasts as had been demonstrated by our previous study with human osteoblasts in culture. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11545623     DOI: 10.1054/plef.2001.0292

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  7 in total

1.  Prostacyclin regulates bone growth via the Epac/Rap1 pathway.

Authors:  Michele R Hutchison; Perrin C White
Journal:  Endocrinology       Date:  2014-11-18       Impact factor: 4.736

Review 2.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 3.  Osteocytes: master orchestrators of bone.

Authors:  Mitchell B Schaffler; Wing-Yee Cheung; Robert Majeska; Oran Kennedy
Journal:  Calcif Tissue Int       Date:  2013-09-17       Impact factor: 4.333

4.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

5.  Prostacyclin suppresses twist expression in the presence of indomethacin in bone marrow-derived mesenchymal stromal cells.

Authors:  Oliver Kemper; Monika Herten; Johannes Fischer; Marcel Haversath; Sascha Beck; Tim Classen; Sebastian Warwas; Tjark Tassemeier; Stefan Landgraeber; Sabine Lensing-Höhn; Rüdiger Krauspe; Marcus Jäger
Journal:  Med Sci Monit       Date:  2014-11-10

6.  Temporal expression and signalling of prostacyclin receptor in the human endometrium across the menstrual cycle.

Authors:  S Battersby; H O D Critchley; A J de Brum-Fernandes; H N Jabbour
Journal:  Reproduction       Date:  2004-01       Impact factor: 3.906

7.  Rationale for prostaglandin I2 in bone marrow oedema--from theory to application.

Authors:  Marcus Jäger; Frank Peter Tillmann; Thomas S Thornhill; Marcus Mahmoudi; Dirk Blondin; Gerd Rüdiger Hetzel; Christoph Zilkens; Rüdiger Krauspe
Journal:  Arthritis Res Ther       Date:  2008-10-03       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.